<DOC>
	<DOCNO>NCT02490436</DOCNO>
	<brief_summary>The purpose study determine whether EGFR-inhibitor cetuximab well placebo treatment neuropathic pain .</brief_summary>
	<brief_title>Novel Treatment Option Neuropathic Pain</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed informed consent anticipate compliance . Pain define `` definite '' neuropathic pain , accord Special Interest Group Neuropathic Pain guideline define `` probable '' NP , accord guideline , confirmatory test positive diagnostic test . Complex regional pain syndrome include despite lack offend lesion , long `` Budapest criterion '' fulfil Neuropathic Pain associate compressive nerve state ( include fail surgery ) CRPS ( accord `` Budapest criterion '' ) PainDETECT score least 13 average pain intensity least 6 /10 last four week . In addition , painDETECT pattern indicate underlying neuropathic pain constantly present . Worst pain intensity high 6 five seven day screen phase , accord Brif Pain Inventory . The patient able distinguish neuropathic pain pain condition , include element nociceptive pain cause disease process . Neuropathic pain duration six thirty month , deem chronic likely irreversible clinical history finding . No new increase neuropathic pain treatment last four week . Standard medical treatment patient ' underlying condition neuropathic pain must consider tried must , accord opinion refer consult pain specialist , judge inappropriate insufficient potential efficacy . Referring physician agreement follow patient study completion accord best possible available pain treatment care . Women childbearing potential men must use acceptable method contraception throughout study , 30 day last study drug administration . Negative pregnancy test within 7 day treatment period appropriate . White blood cell count ≥ 3 × 109 neutrophil ≥ 1.5 × 109/L , platelet count ≥ 100 × 109/L hemoglobin ≥ 6.21 mmol/L ( 10 g/dL ) . Total bilirubin ≤ 1.5 × upper limit reference range AST ALT ≤ 2.5 × upper limit reference range within last 28 day inclusion . Aged 18 Neuropathic pain origin central nervous system . Phantom limb pain significant component nociceptive pain . Ascending distal small fiber peripheral neuropathy . Patients primarily experience pain 'attacks ' , i.e . pattern neuropathic pain depict picture 3 painDETECT . Other pain state may interfere evaluation study neuropathic pain condition . Any underlying medical psychiatric condition , clinical disorder laboratory finding , opinion investigator may interfere study objective . Uncontrolled unstable diabetes . Severe uncontrolled cardiovascular disease ( congestive heart failure NYHA III IV ) , unstable angina pectoris , history myocardial infarction within last twelve month , significant arrhythmia Severe cerebrovascular disease six month prior inclusion . Active ongoing eye skin disorder newly diagnose gastric ulcer may interfere study treatment . History allergic reaction study treatment component , red meat tick bite . Previous treatment EGFRpathway inhibitor . Women pregnant breastfeeding . Participation another clinical trial within past 90 day . Use investigational agent within 90 day prior day 1 study drug . Known drug abuse/alcohol abuse , legal incapacity limited legal capacity reason , opinion investigator precludes subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>